Grifols S A Stock Price, News & Analysis

Grifols has announced a clinical trial set to commence in February 2021 in Spain to evaluate the safety and efficacy of a new COVID-19 treatment utilizing Gamunex®-C, which contains anti-SARS-CoV-2 polyclonal antibodies from recovered plasma donors. The trial will involve approximately 800 asymptomatic patients testing positive for the virus. This treatment is designed to offer immediate post-exposure protection, particularly for vulnerable populations. Results are anticipated in Spring 2021, with the potential to enhance existing vaccination efforts.

Summary not available.

Grifols (NASDAQ: GRFS) announced a partnership with TRC Healthcare on November 12, 2020, to enhance pharmacy education. This collaboration integrates Grifols' PharmacyKeeper, a leading IV Workflow Management system, with TRC's educational resources. The aim is to improve patient safety and care by providing pharmacists with up-to-date drug information and training. The partnership underscores Grifols' commitment to advancing IV room operations and reinforces its leadership position in the pharmacy technology market.

Grifols has commenced a randomized controlled clinical trial for its anti-SARS-CoV-2 hyperimmune globulin aimed at treating COVID-19. Funded by NIAID, this Phase 3 trial will assess safety, efficacy, and tolerability in 500 hospitalized adults across 58 hospitals in 18 countries. This treatment leverages convalescent plasma from recovered COVID-19 patients, potentially enhancing immune response to reduce severe illness risk. Grifols has quickly established a convalescent plasma collection program and is actively participating in over 25 COVID-19 initiatives.

Grifols has launched a clinical trial for its anti-SARS-CoV-2 hyperimmune globulin, aimed at treating COVID-19. This randomized controlled trial will assess the product's safety and efficacy in 500 hospitalized adults across 58 hospitals in 18 countries, including the U.S. and Spain. Funded by NIAID, the trial seeks to enhance immune responses when symptoms appear. Grifols leads multiple COVID-19 initiatives and has developed a robust plasma collection program to support treatment efforts during the pandemic.

Grifols has acquired a plasma fractionation plant in Montreal and 11 plasma collection centers in the U.S. from GC Pharma for a total of US$460 million. This move establishes Grifols as the only large-scale commercial manufacturer of plasma products in Canada, with an annual capacity of 1.5 million liters. The investment aims to enhance self-sufficiency in plasma-derived medicines in Canada and expand Grifols' plasma collection network. The transaction will significantly bolster Grifols' presence in North America, targeting a market known for high plasma consumption.

Grifols has acquired a plasma fractionation plant and purification facilities in Montreal, Canada, for US$370 million, along with 11 U.S.-based plasma centers for US$90 million. This investment, which does not require external financing, marks Grifols as the only large-scale plasma products manufacturer in Canada, enhancing its capacity to produce essential medicines. The acquisition supports Canada's self-sufficiency in plasma-derived therapies and aligns with Grifols' strategy for international growth, particularly in North America, where plasma consumption rates are high.

Grifols (NASDAQ: GRFS) announced its acquisition of Alkahest, Inc. for $146 million on a debt-free basis. The deal aims to leverage Alkahest's expertise in the human plasma proteome to develop innovative therapies for age-related diseases. The transaction is pending antitrust approval and expected to close in early 2021. Alkahest has identified over 8,000 proteins that could lead to new therapeutics and diagnostics. This acquisition aligns with Grifols' mission to enhance its research and development capabilities in plasma-derived medicines.

Grifols has announced its acquisition of Alkahest, Inc. for $146 million, aimed at enhancing its research and development capabilities for age-related diseases. The transaction, debt-free and requiring no additional financing, is subject to antitrust approval and expected to finalize in early 2021. Alkahest specializes in therapies targeting the aging plasma proteome, with over 8,000 proteins identified, promising innovative therapeutic avenues. This strategic move is anticipated to provide synergies in drug development for unmet medical needs associated with aging.